Literature DB >> 26628432

Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.

Young-Seon Kim1, Jung Min Chang2, Hyeong-Gon Moon3, Joongyub Lee4, Sung Ui Shin1, Woo Kyung Moon1.   

Abstract

PURPOSE: To evaluate the accuracy of residual microcalcifications on mammogram (MG) in predicting the extent of the residual tumor after neoadjuvant systemic treatment (NST) in patients with locally advanced breast cancer and to evaluate factors affecting the accuracy of MG microcalcifications using magnetic resonance imaging (MRI) as a reference.
METHODS: The patients who underwent NST and showed suspicious microcalcifications on MG comprised our study population. Clinicopathologic and imaging (MG, MRI) findings were investigated. Agreement between image findings and pathology was assessed and factors affecting the discrepancy were analyzed.
RESULTS: Among 207 patients, 196 had residual invasive ductal carcinoma or ductal carcinoma-in-situ (mean size, 3.78 cm). The overall agreement of residual microcalcifications on MG predicting residual tumor extents was lower than MRI in all tumor subtypes (intraclass correlation coefficient [ICC] = 0.368 and 0.723, p < 0.0001). The agreement of residual MG microcalcifications and pathology was highest in HR(+)/HER2(+) tumors and lowest in the triple-negative tumors (ICC = 0.417 and 0.205, respectively). Multivariate linear regression analysis revealed that a size discrepancy between microcalcifications and histopathology was correlated with molecular subtype (p = 0.005). In HR(+)/HER2(-) and triple-negative subtypes, the mean extents of residual microcalcification were smaller than residual cancer, and overestimation of tumor extent was more frequent in HR(+)/HER2(+) and HR(-)/HER2(+) tumors.
CONCLUSIONS: The extent of microcalcifications on MG after NST showed an overall lower correlation with the extent of the pathologic residual tumor than enhancing lesions on MRI. The accuracy of residual tumor evaluation after NST with MG and MRI is affected by their molecular subtype.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26628432     DOI: 10.1245/s10434-015-4993-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

Review 1.  Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.

Authors:  Octavi Cordoba; Lourdes Carrillo-Guivernau; Carmen Reyero-Fernández
Journal:  Breast Care (Basel)       Date:  2018-07-25       Impact factor: 2.860

2.  Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?

Authors:  Yara Feliciano; Anita Mamtani; Monica Morrow; Michelle M Stempel; Sujata Patil; Maxine S Jochelson
Journal:  Ann Surg Oncol       Date:  2017-01-05       Impact factor: 5.344

3.  Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

Authors:  Bruna M Thompson; Luciano F Chala; Carlos Shimizu; Max S Mano; José R Filassi; Felipe C Geyer; Ulysses S Torres; Giselle Guedes Netto de Mello; Cláudia da Costa Leite
Journal:  Eur Radiol       Date:  2021-10-30       Impact factor: 7.034

Review 4.  Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Xianshu Kong; Qian Zhang; Xuemei Wu; Tianning Zou; Jiajun Duan; Shujie Song; Jianyun Nie; Chu Tao; Mi Tang; Maohua Wang; Jieya Zou; Yu Xie; Zhenhui Li; Zhen Li
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

Review 5.  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Huan Wang; Xiaoyun Mao
Journal:  Drug Des Devel Ther       Date:  2020-06-18       Impact factor: 4.162

6.  Changes in Tumor Stem Cell Markers and Epithelial-Mesenchymal Transition Markers in Nonluminal Breast Cancer after Neoadjuvant Chemotherapy and Their Correlation with Contrast-Enhanced Ultrasound.

Authors:  Xiaoling Leng; Guofu Huang; Lianhua Zhang; Jianbing Ding; Fucheng Ma
Journal:  Biomed Res Int       Date:  2020-11-17       Impact factor: 3.411

7.  Diagnostic performance of digital breast tomosynthesis for predicting response to neoadjuvant systemic therapy in breast cancer patients: A comparison with magnetic resonance imaging, ultrasound, and full-field digital mammography.

Authors:  Ryusuke Murakami; Hitomi Tani; Shinichiro Kumita; Nachiko Uchiyama
Journal:  Acta Radiol Open       Date:  2021-12-20

8.  Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.

Authors:  Valentina Iotti; Sara Ravaioli; Rita Vacondio; Chiara Coriani; Sabrina Caffarri; Roberto Sghedoni; Andrea Nitrosi; Moira Ragazzi; Elisa Gasparini; Cristina Masini; Giancarlo Bisagni; Giuseppe Falco; Guglielmo Ferrari; Luca Braglia; Alberto Del Prato; Ivana Malavolti; Vladimiro Ginocchi; Pierpaolo Pattacini
Journal:  Breast Cancer Res       Date:  2017-09-11       Impact factor: 6.466

9.  Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.

Authors:  Yeong Yi An; Sung Hun Kim; Bong Joo Kang
Journal:  World J Surg Oncol       Date:  2017-11-06       Impact factor: 2.754

10.  Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed.

Authors:  Valentina Iotti; Moira Ragazzi; Giulia Besutti; Vanessa Marchesi; Sara Ravaioli; Giuseppe Falco; Saverio Coiro; Alessandra Bisagni; Elisa Gasparini; Paolo Giorgi Rossi; Rita Vacondio; Pierpaolo Pattacini
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.